This is the authors' abstract. We don't add key points for this paper.
Vildagliptin is an incretin degradation inhibitor that improves beta-cell function in diabetic patients by increasing the insulin secretory tone.
No takes yet. Share an insight, caveat, or question.
Mari et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: